(Q38066416)

English

Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.

scientific article published on January 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

Europe PubMed Central

Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Cécile Thirant

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Hervé Chneiweiss

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Marie-Pierre Junier

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

1 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Proteomics - Clinical Applications

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

79-90

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Astrocytes reverted to a neural progenitor-like state with transforming growth factor alpha are sensitized to cancerous transformation.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The origins of glioma: E Pluribus Unum?

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Neuro-oncology, a decade of temozolomide and beyond

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Mechanisms of chemoresistance to alkylating agents in malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Identification of human brain tumour initiating cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Cancerous stem cells can arise from pediatric brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

BMI1 Confers Radioresistance to Normal and Cancerous Neural Stem Cells through Recruitment of the DNA Damage Response Machinery

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A restricted cell population propagates glioblastoma growth after chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Suppression of uPA and uPAR Attenuates Angiogenin Mediated Angiogenesis in Endothelial and Glioblastoma Cell Lines

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Matrix metalloproteinases and the regulation of tissue remodelling

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Angiogenesis in brain tumours

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hypoxia-inducible factors, stem cells, and cancer

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

CD133 identifies perivascular niches in grade II-IV astrocytomas

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Glioblastoma stem-like cells give rise to tumour endothelium.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Transdifferentiation of glioblastoma cells into vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Signal transduction inhibitors and antiangiogenic therapies for malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Novel anti-angiogenic therapies for malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Advances in the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Alternative lengthening of telomeres in human glioma stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Acidic stress promotes a glioma stem cell phenotype.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A specialized vascular niche for adult neural stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Heterogeneity maintenance in glioblastoma: a social network

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A perivascular niche for brain tumor stem cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Integrin alpha 6 regulates glioblastoma stem cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Endothelial cell heterogeneity

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Endothelial cell diversity revealed by global expression profiling

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Modelling of the blood-brain barrier in drug discovery and development.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Off-tumor target--beneficial site for antiangiogenic cancer therapy?

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

VEGF receptor signalling - in control of vascular function

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A role for VEGF as a negative regulator of pericyte function and vessel maturation

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Antiangiogenic therapies for high-grade glioma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Combining antiangiogenics to overcome resistance: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

DLG1/SAP97 modulates transforming growth factor alpha bioavailability

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Autocrine semaphorin 3A signaling promotes glioblastoma dispersal

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A new method for predicting signal sequence cleavage sites

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Secretion of hepatoma-derived growth factor is regulated by N-terminal processing

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hepatoma-derived growth factor. Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF).

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Investigation of serum proteome alterations in human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Chronic DLL4 blockade induces vascular neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FPRCA.201200102

21 January 2018

Blood-brain barrier-specific properties of a human adult brain endothelial cell line

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1096/FJ.04-3458FJE

Identifiers

10.1002/PRCA.201200102

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23229792%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38066416&oldid=1647782037"